Cellectar to Participate at the Oppenheimer Rare & Orphan Disease Summit on

Cellectar to Participate

at the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021

May 14, 2021 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the

discovery and development of drugs for the treatment of cancer, today announced the company will participate and be available for 1x1

meetings at the following upcoming conference:

Orphan Disease Summit

A replay of the presentation

will be available on the Events page of the company website.

Cellectar Biosciences

is focused on the discovery and development of drugs for the treatment of cancer. The company is developing proprietary drugs independently

and through research and development collaborations. The company's core objective is to leverage its proprietary Phospholipid Drug

Conjugate (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better

safety as a result of fewer off-target effects. The company's PDC platform possesses the potential for the discovery and development

of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development

The company's product

pipeline includes CLR 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope) and proprietary preclinical

PDC chemotherapeutic programs and multiple partnered PDC assets.

For more information, please visit www.cellectar.com

or join the conversation by liking and following us on the company's social media channels: Twitter,

LinkedIn, and Facebook.